On the advanced prostate cancer group I moderate there has been a discussion about the health risks of using Fosamax for an extended period of time. The risks of long term therapy remains unclear and mixed. The Physicans Desk Reference (PDR) indicates they have no idea what effects Fosamax may have after four years! Fosamax [...]
GTx, Inc. (Nasdaq: GTXI) has conducted a number of clinical trials using toremifene citrate in both the treatment of breast and prostate cancer. Older women and men as well as women and men being treated for both breast and prostate cancers are subject to bone loss leading to an increased risk of falls and fractures. [...]
Amgen just completed, with positive results, a three-year Phase 3 placebo-controlled trial which evaluated denosumab for the treatment of bone loss (reduction of bone mineral density –BMD) in men undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer. One of the more common and significant side effects of ADT is loss of BMD. This loss [...]
Oh no, another not so very clear issue for men with prostate cancer has emerged! According to an article written by Tara Parker-Pope in the New York Times, bisphosphonates (i.e. Fosamax), has been reported, in some rare occasions, to actually cause weaker bones that lead to an unusual type of fracture of the femur. Bisphosphonates [...]
Researchers from the Massachusetts General Hospital have reported at the 2008, 99th annual meeting of the American Association for Cancer Research (AACR) in San Diego, April 12-16.1 that Fareston® (toremifene citrate) decreases the risk of new vertebral fractures in men with prostate cancer receiving androgen deprivation therapy (ADT). As we all know from our own [...]